Dengue vaccine could be ready by 2015: Sanofi

Jun 10, 2011

French drugs group Sanofi said Friday that its vaccine against dengue, a mosquito-borne infection that kills thousands of people around the world each year, could be launched in about four years.

"The vaccine could be available... around 2015," Jean Lang, head of at the group's subsidiary Sanofi-Pasteur, told reporters in Bangkok.

The launch date is dependent on regulatory approval in each country based on the results of trials.

The vaccine is the first for dengue to undergo advanced "Phase III" clinical trials -- the final stage before the results are submitted for regulatory approval.

About 4,000 children in the central Thai province of Ratchaburi, one of the worst affected areas in the country, are participating in a study that aims to establish the efficacy of the vaccine.

Dengue causes severe, in about 50 million people every year, mainly in developing countries. There are four strains, one of which is a potentially lethal type.

Dengue has reemerged in recent years as a serious public health threat in . There is currently no treatment, cure or vaccine.

Explore further: Supercomputers link proteins to drug side effects

add to favorites email to friend print save as pdf

Related Stories

Thailand developing dengue vaccine: researcher

Feb 22, 2011

Researchers in Thailand say they have developed a prototype vaccine against dengue fever and will conduct further tests with the aim of bringing it to market within a decade.

US researchers hopeful for dengue vaccine

Feb 17, 2011

Promising advances have been made in the testing of possible vaccines to prevent the mosquito-borne dengue virus, which kills 25,000 people every year, researchers said Thursday.

Recommended for you

Supercomputers link proteins to drug side effects

13 hours ago

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

20 hours ago

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments : 0